Targeting Drug Resistance 2: RAS Signaling

• 1868 · PDF 基于耐药细胞组合的多靶点联合方案与机制发现以克服KRAS抑制剂耐药 Resistant cell panel-based discovery of multi-target combinations and mechanisms to overcome KRAS inhibitor resistance Lili Chai, Yue Zhai, Xue Yang, Zhengtai Li, Ying Bi, Yan Zhang, Tj (Tiejun) Bing
• 1869 · PDF 联合FGTI-2734与MRTX1133抑制KRAS G12D胰腺癌中ERK驱动的耐药 Combining FGTI-2734 and MRTX1133 to suppress ERK-driven resistance in KRAS G12D pancreatic cancer Deblina Ghosh, Aslamuzzaman Kazi, Hitesh Kumar Kantilal Vasiyani, Vignesh Vudatha, Nicolas Lecomte, Christine A. Iacobuzio-Donahue, Jose G. Trevino, Said M. Sebti
• 1870 1870 表征KRAS突变型肺癌中药物诱导的转录重编程 Characterizing drug-induced transcriptional reprogramming in KRAS mutant lung cancer Wafa Malik, Anurag Singh, Laurent Sansregret, Aaron N. Hata
• 1871 · PDF RAS与ICB联合抑制靶向化疗耐药胰腺癌中NF-κB驱动的免疫逃逸 Combined RAS and ICB inhibition targets NF-KB-driven immune evasion in chemoresistant pancreatic cancer Kevin Christian Gulay, Alexei Martsinkovskiy, Isabella Ng, Deepa Sheik Pran Babu, Jay Patel, Rithika Medari, Ponmathi Panneerpandian, Tatiana Hurtado de Mendoza, Andrew Lowy, Herve Tiriac
• 1872 · PDF 一项高通量联合筛选确定NT-1为克服KRAS G12D抑制剂耐药的优效化合物 A high-throughput combination screen identifies NT-1 as a superior compound to overcome KRAS G12D inhibitor resistance Natalie Thielen, Chaoyuan Kuang, Ning Wei, Seiya Kitamura, Emiko Nagai
• 1873 · PDF Atebimetinib对MEK的深度周期性抑制可约束RAS突变肿瘤患者MAPK轴的适应性与获得性改变 Atebimetinib's deep cyclic inhibition of MEK constrains MAPK-axis adaptive and acquired alterations in patients with RAS-mutant tumors Jason S. Kim, Jason Funt, Jenny Zhang, Sarah Kolitz, Praveen Nair, Vinny Hayreh, Benjamin J. Zeskind, Igor Matushansky, Brett M. Hall
• 1874 · PDF 长期KRAS-MAPK抑制激活干扰素信号以促进细胞可塑性并揭示联合治疗的新靶点 Prolonged KRAS-MAPK inhibition activates interferon signaling to promote cellular plasticity and uncover novel targets for combination therapy Ashenafi Shiferaw Bulle, Yali Chen, Huaping Li, Hung-Po Chen, Iftikhar Ali Khawar, Lin Li, Yu Wang, Peng Liu, Vikas Kumar Somani, Richard Kurupi, Sapana Prakashrao Bansod, Son Bang Le, Marianna Ruzinova, David D Tran, Kian-Huat Lim
• 1875 · PDF 通过EGFR导向的倒置嵌合RNAi分子对KRAS G12V和pan-TEAD进行协同共靶向 Synergistic co-targeting of KRAS G12V and pan-TEAD by an EGFR-directed, inverted chimeric RNAi molecule Lyla Stanland, Alessandro Porrello, Sarah R. McLarnon, Lori L. O'Brien, Chad V. Pecot
• 1876 · PDF 阿扎胞苷预处理使RAS突变的继发性AML对pan-RAS抑制剂RMC-7977增敏 Pre-treatment with azacytidine sensitizes RAS mutated secondary AML to the pan-RAS inhibitor RMC-7977 Xinghan Zeng, Yuju An, Brandy Perkins, Tessa Seale, Erotokritos Georgantzinos, Theodora Chatzilygeroudi, Bogdan Paun, Maximillian Stahl, Mark J. Levis, Styliani Karanika, Alexander Ambinder, Sandra Misale, Theodoros Karantanos
• 1877 · PDF 结直肠癌对三元复合物抑制剂的获得性耐药 Acquired resistance to Tri-complex inhibitors in colorectal cancer Sabine Jurado, Simone Lieb, Marco H. Hofmann, Mark Pearson, Phillipp Schmalhorst, Krzysztof Zak
• 1878 · PDF 在Ras突变细胞中共靶向B-Raf和ACLY导致细胞活力协同丧失和凋亡 Cotargeting B-Raf and ACLY in Ras mutant cells leads to synergistic loss of cell viability and apoptosis Nancy A. Krucher, Bryce D. Aierstok, Sabrina Bergesio, Gabriella J. Galgano, Morgan E. Strecker
• 1879 · PDF 在广泛的癌细胞系模型集合中对KRAS G12C抑制剂固有耐药和获得性耐药的表征 Characterization of intrinsic and acquired resistance to KRAS G12C inhibitors across a broad collection of cancer cell line models Jeffrey J. Kooijman, Kirsten J. W. Kevenaar, Imke P. M. Smits, Daphne J. F. Kluitmans, Laura D. R. van Zelst, Bente Timmers, Tsang W. Lam, Jeroen A. D. M. de Roos, Yvonne Grobben, Janneke J. T. M. Melis, Guido J. R. Zaman, Jorg C. J. Benningshof
• 1880 · PDF 解构癌基因协同作用的范式：靶向MYC以增强对KRAS抑制剂的响应并克服耐药 Deconstructing the paradigm of oncogene cooperation: Targeting MYC to enhance response and overcome resistance to KRAS inhibitors Daniel Capitán-Leo, Íñigo González-Larreategui, Magda Arnal, Judit Grueso, Lorena Sansegundo-Barbosa, Hugo Thabussot, Irene Ferrer, Silvestre Vicent, Marie-Eve Beaulieu, Sílvia Casacuberta-Serra, Laura Soucek
• 1881 · PDF 理解KRAS G12C突变型非小细胞肺癌中sotorasib耐药的进化和生态学机制 Understanding evolutionary and ecological mechanisms of sotorasib resistance in KRAS G12C-mutant non-small cell lung cancer Jinling Wu, Mina Nguyen Dinh, Arda Durmaz, Maximilian Strobl, Jacob G. Scott
• 1882 · PDF 胰腺癌daraxonrasib耐药的患者来源异种移植模型的构建 Generation of daraxonrasib-resistant patient-derived xenograft models of pancreatic cancer Nina Dashti-Gibson, Amy L. Olex, Rachel K. Myrick, Alexa M. Barber, David C. Boyd, Emily K. Zboril, Katarzyna M. Tyc, Mikhail G. Dozmorov, Guang-Yu Yang, Nicholas T. Woods, Jose G. Trevino, J. Chuck Harrell
• 1883 · PDF 通过可成药靶点合集CRISPR-Cas9文库筛选预测胰腺癌类器官在KRAS G12D抑制下的耐药机制 Predicting resistance mechanisms in pancreatic cancer organoids under KRAS G12D inhibition via pooled CRISPR-Cas9 druggable library screen Lauryn E. Flannagan, Michela Cadarso, Md Shahadat Hossan, Molly A. Nellen, Sean J. McIlwain, C. Dustin Rubinstein, Sean Ronnekleiv-Kelly, Jeremy D. Kratz
• 1884 · PDF 跨KRAS突变型患者来源模型对泛RAS(ON)抑制剂daraxonrasib（RMC-6236）敏感性和耐药性的分子决定因素 Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz
• 1885 · PDF USP7抑制剂通过有效对抗反馈信号通路协同增强KRAS G12C抑制剂的抗癌效果 USP7 inhibitor synergistically enhanced the anticancer effect of the KRAS G12C inhibitor by effectively countering feedback signaling pathways​ Yuanyuan Gao, Keqiang Zhang, Wendong Li, Chunxia Su, John Liu, Lilian Gu, Mahima Raul, Dan Raz
• 1886 · PDF 配体将EGFR的重新激活与NSCLC中对KRAS G12C抑制剂的耐药联系起来 Ligand links EGFR reactivation to resistance against KRAS G12C inhibitors in NSCLC Shigeki Nanjo, Yifeng Liu, Hayato Koba, Seiji Yano
• 1887 · PDF 实时解析KRAS G12C LUAD肿瘤中SCLC的出现：靶向治疗耐药的案例研究 Real-time dissection of SCLC emergence in a KRAS G12C LUAD tumour: A case study of targeted therapy resistance Priyanka Gopal
• 1888 · PDF 揭示PDAC模型中MRTX1133耐药的机制 Unveiling mechanisms of MRTX1133 resistance in PDAC models Qin Li
• 1889 · PDF 阐明并克服KRAS G12D突变肿瘤内在耐药机制的治疗策略 Elucidation and therapeutic strategies to overcome intrinsic resistance mechanisms in KRAS G12D-mutant tumors Ryo Sawada, Tadaaki Yamada, Yuki Katayama, Koichi Takayama
• 1890 · PDF 靶向核糖核苷酸还原酶以克服急性髓系白血病中的FLT3抑制剂耐药 Targeting ribonucleotide reductase to overcome FLT3 inhibitor resistance in acute myeloid leukemia Zhen Tian, Peng Wang, Stacia Octaviani, Yahui Li, Yun Liao, Xiaolei Liu, Zhaorui Lian, Hong Zheng, Elliot Stieglitz, Catherine C. Smith, Jian Huang
• 1891 · PDF Minnelide增强泛KRAS抑制剂RMC-6236在胰腺癌临床前模型中的抗肿瘤活性 Minnelide enhances the antitumor activity of pan-KRAS inhibitor RMC-6236 in preclinical models for pancreatic cancer Edgar Banuelos, Jaeger Moore, Mohana Velagapudi, Ashok Saluja, Daniel D. Von Hoff, Haiyong Han

在会议检索中浏览本分会场